Voice of the Patient: Peer “Ambassadors” Help Recruitment at Aegerion
This article was originally published in RPM Report
Executive Summary
In the ultra-orphan, ultra-priced segment where the recruitment of each patient is a major commercial event, the voice of existing patients can be very important.
You may also be interested in...
Will Aegerion Need Another TV Interview To Satisfy FDA After Juxtapid Citation?
FDA asks for correction in warning letter objecting to CEO statements on CNBC’s “Fast Money” that touted the rare lipid disorder treatment.
Aegerion CEO Talks Juxtapid Launch, Competitive Threats At BIO
Aegerion CEO Marc Beer outlined why he thinks Juxtapid will emerge as the first-line treatment of choice for the orphan lipid disease HoFH over Genzyme/Isis’ Kynamro despite its significantly higher cost during an interview at the BIO CEO & Investor conference; the two drugs are facing off to win patients in an ultra-niche market that could total just 3,000 patients in the U.S.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.